NYSE:NVO - Novo Nordisk A/S Stock Price, Forecast & News

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Novo Nordisk A/S announced a Semi-Annual dividend on Friday, August 9th. Shareholders of record on Monday, August 19th will be paid a dividend of $0.318 per share on Tuesday, August 27th. The ex-dividend date of this dividend is Friday, August 16th. View Novo Nordisk A/S's Dividend History.

Novo Nordisk A/S announced that its board has initiated a share repurchase plan on Friday, February 2nd 2018, which permits the company to buyback outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Stock buyback plans are typically an indication that the company's management believes its shares are undervalued.

Novo Nordisk A/S (NYSE:NVO) issued its quarterly earnings results on Friday, November, 1st. The company reported $0.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.02. The business had revenue of $4.51 billion for the quarter, compared to analysts' expectations of $4.55 billion. Novo Nordisk A/S had a return on equity of 75.48% and a net margin of 32.44%. View Novo Nordisk A/S's Earnings History.

Novo Nordisk A/S is scheduled to release their next quarterly earnings announcement on Friday, February 7th 2020. View Earnings Estimates for Novo Nordisk A/S.

12 brokers have issued 1-year price objectives for Novo Nordisk A/S's stock. Their forecasts range from $48.61 to $400.00. On average, they anticipate Novo Nordisk A/S's share price to reach $181.58 in the next year. This suggests a possible upside of 197.3% from the stock's current price. View Analyst Price Targets for Novo Nordisk A/S.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novo Nordisk A/S.

Headlines about NVO stock have trended extremely negative on Sunday, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Novo Nordisk A/S earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Novo Nordisk A/S.

Some companies that are related to Novo Nordisk A/S include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), AstraZeneca (AZN), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Bayer (BAYRY) and Celgene (CELG).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), QUALCOMM (QCOM), Johnson & Johnson (JNJ), AT&T (T), NVIDIA (NVDA), Starbucks (SBUX), Cisco Systems (CSCO) and Alibaba Group (BABA).

Novo Nordisk A/S's stock is owned by many different of institutional and retail investors. Top institutional investors include Scout Investments Inc. (0.01%), Ferguson Wellman Capital Management Inc. (0.01%), Janney Montgomery Scott LLC (0.00%), Atwater Malick LLC (0.00%), Commerzbank Aktiengesellschaft FI (0.00%) and Traynor Capital Management Inc. (0.00%). View Institutional Ownership Trends for Novo Nordisk A/S.

NVO stock was sold by a variety of institutional investors in the last quarter, including Loring Wolcott & Coolidge Fiduciary Advisors LLP MA, Commerzbank Aktiengesellschaft FI, First Hawaiian Bank, Scout Investments Inc., Norris Perne & French LLP MI, Smithbridge Asset Management Inc. DE, Brookmont Capital Management and Ferguson Wellman Capital Management Inc.. View Insider Buying and Selling for Novo Nordisk A/S.

NVO stock was acquired by a variety of institutional investors in the last quarter, including Chemung Canal Trust Co., Janney Montgomery Scott LLC, Mckinley Capital Management LLC Delaware, We Are One Seven LLC, Calamos Advisors LLC, Ingalls & Snyder LLC, SeaCrest Wealth Management LLC and Atwater Malick LLC. View Insider Buying and Selling for Novo Nordisk A/S.

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVO stock can currently be purchased for approximately $61.08.

Novo Nordisk A/S has a market capitalization of $144.64 billion and generates $17.72 billion in revenue each year. The company earns $5.91 billion in net income (profit) each year or $2.52 on an earnings per share basis. Novo Nordisk A/S employs 43,202 workers across the globe.View Additional Information About Novo Nordisk A/S.

The official website for Novo Nordisk A/S is http://www.novonordisk.com/.

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]